» Articles » PMID: 18508998

Estrogen Signaling Ability in Human Endometrial Cancer Through the Cancer-stromal Interaction

Overview
Specialties Endocrinology
Oncology
Date 2008 May 30
PMID 18508998
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The estrogen pathway plays an important role in the etiology of human endometrial carcinoma (EC). We examined whether estrogen biosynthesis in the tumor microenvironment promotes endometrial cancer. To examine the contribution of stromal cells to estrogen signaling in EC, we used reporter cells stably transfected with the estrogen response element (ERE) fused to the destabilized green fluorescent protein (GFP) gene. In this system, the endometrial cancer stromal cells from several patients activated the ERE of cancer cells to a variable extent. The GFP expression level increased when testosterone, a substrate for aromatase, was added. The effect was variably inhibited by aromatase inhibitors (AIs), although the response to AIs varied among patients. These results suggest that GFP expression is driven by estrogen synthesized by aromatase in the endometrial cancer stromal cells. In a second experiment, we constructed an adenovirus reporter vector containing the same construct as the reporter cells described above, and visualized endogenous ERE activity in primary culture cancer cells from 15 EC specimens. The GFP expression levels varied among the cases, and in most primary tissues, ERE activities were strongly inhibited by a pure anti-estrogen, fulvestrant. Interestingly, a minority of primary tissues in endometrial cancer showed ERE activity independent of the estrogen-ER pathway. These results suggest that AI may have some therapeutic value in EC; however, the hormonal microenvironment must be assessed prior to initiating therapy.

Citing Articles

Microenvironmental elements singularity synergistically regulate the behavior and chemosensitivity of endometrioid carcinoma.

Morito S, Kawasaki M, Nishiyama M, Sakumoto T, Hashiguchi M, Narita T Hum Cell. 2023; 36(3):1147-1159.

PMID: 36853404 DOI: 10.1007/s13577-023-00886-7.


Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line.

Rush C, Blanchard Z, Polaski J, Osborne K, Osby K, Vahrenkamp J Sci Rep. 2022; 12(1):19731.

PMID: 36396974 PMC: 9672046. DOI: 10.1038/s41598-022-24211-8.


Endometrial Cancer in Aspect of Forkhead Box Protein Contribution.

Adamczyk-Gruszka O, Horecka-Lewitowicz A, Gruszka J, Wawszczak-Kasza M, Strzelecka A, Lewitowicz P Int J Environ Res Public Health. 2022; 19(16).

PMID: 36012038 PMC: 9408638. DOI: 10.3390/ijerph191610403.


Regulation of aromatase in cancer.

Molehin D, Rasha F, Layeequr Rahman R, Pruitt K Mol Cell Biochem. 2021; 476(6):2449-2464.

PMID: 33599895 DOI: 10.1007/s11010-021-04099-0.


ERα increases endometrial cancer cell resistance to cisplatin via upregulation of BAG3.

Abe S, Iwasaki M, Habata S, Mariya T, Tamate M, Matsuura M Oncol Lett. 2020; 21(1):20.

PMID: 33240426 PMC: 7681203. DOI: 10.3892/ol.2020.12281.